Xvivo Perfusion Q1: High profitability, high activity
Sales in Q1 came in slightly higher than our forecast due to higher-than-expected sales of durable goods. The balance in the product mix resulted in a slightly lower gross margin than expected, but the EBITDA result was in line with expectations. The company reported some updates on the research portfolio, indicating continued high activity. Our fair value remains unchanged at SEK 105 per share.